Search Within

Carol Portlock

  1. "Hematologic Malignancies, Division of"
Formats
  1. Journal Article (104)
  2. Meeting Abstract (88)
  3. Book Section (10)
  4. Conference Paper (1)
  5. Research Letter (1)
Groups
  1. Center for Hematologic Malignancies (204)
  2. Department of Medicine (204)
  3. Hematologic Malignancies, Division of (204)
  4. Lymphoma (204)
  5. Survivorship Research (96)
  6. Population Sciences Research Program (64)

More Groups

People
  1. Andrew Zelenetz (114)
  2. Craig Moskowitz (106)
  3. David Straus (100)
  4. Ariela Noy (91)
  5. Paul Hamlin (80)
  6. Steven Horwitz (60)

More People

Years
  1. 2024 (1)
  2. 2021 (3)
  3. 2020 (1)
  4. 2019 (6)
  5. 2018 (2)
  6. 2017 (12)

More Years

Publications
  1. Blood (63)
  2. Journal of Clinical Oncology (22)
  3. Annals of Oncology (16)
  4. Cancer (8)
  5. British Journal of Haematology (7)
  6. Leukemia and Lymphoma (7)

More Publications

Publishers
  1. American Society of Hematology (66)
  2. American Society of Clinical Oncology (22)
  3. Oxford University Press (16)
  4. Wiley Blackwell (14)
  5. Elsevier Inc. (12)
  6. Lippincott Williams & Wilkins (11)

More Publishers

Results (204)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Whole-body diffusion-weighted MR imaging in lymphoma surveillance
    Meeting Abstract

    Rademaker, J.; Ryan, D.; Matasar, M.; Portlock, C.
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Defining progression free survival after multiple lines of therapy and impact of dynamic changes in FLIPI for multiply relapsed follicular lymphoma in the rituximab era
    Meeting Abstract

    Batlevi, C.; Alperovich, A.; Ni, A.; Soumerai, J.; Smith, K.; Ying, Z.; Caron, P.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Time from prognosis to 2nd treatment is a promising surrogate for overall survival in patients with advanced stage follicular lymphoma
    Meeting Abstract

    Soumerai, J. D.; Ni, A.; Batlevi, C.; Alperovich, A.; Bantilan, K. S.; Palomba, M.; Gerecitano, J. F.; Noy, A.; Hamlin, P.; Moskowitz, C. H.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • A Phase I study of ibrutinib combined with rituximab, ifosfamide, carboplatin, and etoposide in patients with relapsed or primary diffuse large B-cell lymphoma
    Meeting Abstract

    Sauter, C. S.; Matasar, M. J.; Schoder, H.; Drullinsky, P.; Gerecitano, J.; Kumar, A.; Noy, A.; Palomba, M. L.; Portlock, C. S.; Straus, D. J.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Baseline metabolic tumor volume is an independent prognostic factor for relapsed and refractory Hodgkin lymphoma patients receiving PET-adapted salvage therapy with brentuximab vedotin and augmented ICE
    Meeting Abstract

    Moskowitz, A. J.; Schöder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Outcome of initial observation in mantle cell lymphoma
    Meeting Abstract

    Kumar, A.; Ying, Z.; Alperovich, A.; Dogan, A.; Hamlin, P. A. Jr; Moskowitz, C. H.; Portlock, C. S.; Zelenetz, A. D.; Zhang, Z.; Woo, K. M.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Outcomes of follicular lymphoma patients by dynamic FLIPI at diagnosis and initial treatment in the post-rituximab era
    Meeting Abstract

    Batlevi, C.; Alperovich, A.; Smith, K.; Ying, Z.; Soumerai, J. D.; Copeland, A. R.; Joffe, E.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Benchmark of progression free survival for multiple lines of therapy in follicular lymphoma treated in the rituximab era
    Meeting Abstract

    Alperovich, A.; Batlevi, C.; Smith, K.; Ying, Z.; Soumerai, J. D.; Copeland, A. R.; Joffe, E.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • PET-adapted therapy with brentuximab vedotin and augmented ICE for relapsed/refractory Hodgkin lymphoma - Lack of Improvement with 3 versus 2 cycles of weekly brentuximab vedotin
    Meeting Abstract

    Moskowitz, A. J.; Schöder, H.; Yahalom, J.; McCall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; Hamlin, P. A.; Horwitz, S.; Kobos, R.; more...
    Haematologica (2016)

    Fulltext@MSK | Save
  • Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
    Journal Article

    Kumar, A.; Casulo, C.; Yahalom, J.; Schöder, H.; Barr, P. M.; Caron, P.; Chiu, A.; Constine, L. S.; Drullinsky, P.; Friedberg, J. W.; more...
    Blood (2016)

    Fulltext@MSK | Save